item management s discussion and analysis of financial condition and results of operations general medstone manufactures  markets and maintains lithotripters  and continues to expand its fee for service program to supply lithotripsy equipment to providers on a per procedure basis 
the lithotripters manufactured by medstone is approved to treat both kidney stones and gallstones 
the company is also marketing a urology imaging and treatment table  used for various urological functions  mobile urology and pain management table to serve the mobile treatment market and various radiology room equipment  capitalizing on the relationships that the company has with radiology equipment manufacturers 
to date  the company s consolidated revenues have come primarily from medstone s lithotripsy business 
as a manufacturer of medical devices  the company has been vertically integrating by offering its medical devices directly to providers 
it currently offers lithotripsy procedures using mobile systems  two fixed sites and transmobile lithotripters located throughout the united states on a per procedure basis 
with the ability to offer quality equipment at reasonable prices  medstone intends to continue the growth of this manufacturer direct business 
in june  the company completed the acquisition of a interest in northern nevada  a lithotripsy partnership which deals directly with patient and insurers  and also founded upr as a majority owned subsidiary of the company  to expand the company s service orientation to the urologist practitioner 
both entities signify the company s emphasis on growth through expansion of relationships and acquisition 
in march  the company completed the acquisition of a interest in southern idaho lithotripsy associates llc  another operator of retail lithotripsy operations in southern idaho  and operating results have been consolidated effective march  in april  the company purchased certain assets of creos  ltd  a manufacturer of high performance x ray generators and a supplier to the company 
the company then commenced manufacturing operations in a facility  located in fife  scotland  formerly occupied by creos  ltd 
in october  the company purchased the outstanding shares of zenith medical systems  ltd  a distributor of major imaging equipment to the british national health service  located in manchester  england 
both acquisitions operating results have been consolidated effective with their respective acquisition dates 
goodwill represents approximately and of the company s total assets and stockholders equity  respectively  at december  goodwill resulted from the excess of the purchase price of northern nevada  southern idaho and zenith medical systems  ltd 
over the fair value of the net assets acquired 
goodwill is being amortized over periods ranging from to years  the expected period of benefit  using the straight line method 
the company reviews goodwill and other long lived assets for impairment whenever changes in circumstances indicate that the carrying value of the asset may not be recoverable 
based upon the company s analysis  which includes a comparison of the carrying amount of such assets to the company s historical actual cash flows and estimated future undiscounted cash flows  the company is not aware of any material portion of goodwill or other long lived assets which will dissipate over a shorter period than the amortization period used 
from time to time  the company makes investments in businesses which are accounted for under the equity method 
during  the company made an investment  including loans  in medicredit 
com aggregating million 
during and  the company made an aggregate investment in k 
biotech of  the company s share of losses in unconsolidated subsidiaries in  related to medicredit 
com  approximated  no earnings or losses in unconsolidated subsidiaries were recognized in or the company does not have additional financial commitments to these unconsolidated subsidiaries 
the future performance of the unconsolidated subsidiaries is uncertain and therefore  the company may recognize earnings or losses in unconsolidated subsidiaries in the future 
the company began the year with approximately million in cash and short term investments  no debt  inventories of million  and total assets of million 
after the purchase of million of treasury stock  an investment in and lendings to medicredit totaling million and fixed asset additions of million  partially offset by proceeds from the sale of long term investments of million  the company ended the year with approximately million in cash and short term investments  no debt  inventories of million and total assets of million 
through its research and development  acquisitions and clinical submissions  management believes that it is hiring and retaining the appropriate personnel necessary to continue growth and development of the company s product lines and brand recognition 
from time to time  the company is subject to legal actions and claims for personal injuries or property damage related to patients who use its products 
the company has obtained a liability insurance policy providing coverage for product liability and other claims 
management does not believe that the resolution of any current proceedings will have a material financial impact on the company or the consolidated financial statements 
results of operations year ended december  compared to year ended december  the company recorded total revenue of million in  a decrease compared to the million in total revenue recognized for the year ending december  revenues from procedures  maintenance fees and fee for service decreased to million in when compared to the million in revenue in pricing pressures continue to force per patient charges lower as competing equipment has saturated the market with low cost  transportable lithotripsy equipment 
patient volume and per patient fees both decreased during as sites continued to transition to lower cost equipment and more sites are selecting a flat daily or monthly fee in anticipation of the release of final stark ii regulations which occurred on january  procedure fees from third party equipment decreased by  the second year in a row with decreased fees 
although patient volume increased by in when compared to fees per procedure decreased 
the company experienced an increase in volume as sts t units  which commenced shipment in  reached full utilization and also renewed interest in the company s lithotripsy products was achieved due to the approval of the gallstone procedure 
revenue from radiographic supplies increased in the current year due to a full year of activity from both the medstone ltd  and zenith operations and additional activity from the expanding product offerings from the company during equipment revenues decreased by in when compared to the same period in as the number of lithotripters sold decreased to in  compared to in and average sales prices decreased slightly 
offsetting this decrease in lithotripters was the introduction of the imaging tables in  with a total of various units sold in this equipment included pain management tables  radiology tables and portable urology tables along with the imaging systems associated with several unit sales 
interest income increased by in the current year when compared to the same period of the prior year due to higher investment yields even though the average invested balance has decreased substantially 
costs on recurring revenue increased to million  or of recurring revenue in  compared to million  or of recurring revenue in due to the continuation of the company s program of placement of a large number of fixed site fee for service lithotripsy units at hospitals and surgery centers 
it is expected that these units will drive long term patient volume growth with the continuous availability of equipment  along with the expectation of additional volume due to the gallstone approval 
costs of providing maintenance increased also due to the higher number of company owned units in service 
cost of equipment sales increased to million in  or of sales in the current year compared to million  or  for the year ended december  this increase is due to the lower margin associated with the sale of radiology equipment when compared to the historical higher margin on lithotripsy equipment 
lithotripsy equipment margins deteriorated slightly due to unabsorbed overhead expenses due to lower actual production levels when compared to plan 
research and development costs decreased by  or  in the twelve months ending december  when compared to the same period of this decrease is due to the majority of the development work on the uropro urology imaging table occurring earlier in and reduced staffing after completion in of the final development of the sts t 
selling costs increased by  or  for the year ending december  compared to the same period in due to higher advertising  tradeshow and consulting expenses with the introduction of the new imaging table products 
the company has also increased its efforts to sell into the government contract market and is incurring expenses to establish reimbursement guidelines for gallstone lithotripsy 
general and administrative expenses increased by  or in the twelve months ended december  compared to the same period in the prior year due to higher consulting expenses for the gallstone post approval work  higher audit expenses due to the expanded scope of the company s operations  and a full year s expenses in medstone ltd 
gain on sale of investments was approximately  in the twelve months ending december  compared to  in the same period of in  the company sold  shares of cardiac science  inc common stock and  shares of genstar common stock  while in the company sold warrants to purchase  shares of cardiac science common stock 
the net book value of these sales was minority interest in subsidiaries income increased by  or in the twelve months ended december  when compared to the same period of the prior year due to substantially higher activity in the northern nevada and southern idaho operations 
also the company  through its equity investment in medicredit  recognized a  expense for its portion of the operating losses of medicredit from april  through december  provision for income taxes for the year decreased by  as a result of lower taxable income in the current year when compared to the same period of year ended december  compared to year ended december  total revenue of million in represented a decrease in revenue when compared to million in  breaking a string of several years of continuous revenue growth 
results were lower in the procedure  maintenance and management fee revenue partially offset by an increase in the equipment revenue generated by s sales activity 
revenue from procedure  maintenance fees and fee for service decreased to million in  an decrease  when compared to the million in revenue in this decline was due to the market pressures of the widespread availability of transportable lithotripters that caused patient volume to shift as customers purchased lower cost lithotripsy systems and average revenue per patient decreased 
with the lower price for transportable technology  some larger patient volume customers chose to purchase equipment from the company or its competitors and price concessions were instituted for continuing customers 
in  procedure revenue from third party owned equipment decreased by compared to the prior year  due to declines in both volume and lower per procedure fees 
maintenance fees decreased by in the current period when compared to due to lower average contract prices and a lower number of sites under maintenance contracts 
the company also realized revenue of  in from sales of the imaging product lines acquired with the zenith and ltd operations 
net equipment sales in increased to million  or  from million for the comparable period of the prior year 
this was due to the increased shipments of equipment related to the introduction of the sts t transportable lithotripter in  even though transportable lithotripters carry a lower average unit sales price when compared to the fixed unit models 
the activity level of equipment upgrades remained level in the current year compared to the prior year 
interest income increased by  or  in the year ended december  when compared to the same period of the prior year as average invested cash balances increased even as yields remained level from year to year 
costs on recurring revenue increased to million in  or a increase when compared to the million in due to the company s strategy of placing sts t equipment in customer sites on a permanent basis  making the technology always available to the customer  rather than a scheduled service program 
this approach has a large up front investment with the results reflected in the patient volume as utilization increases 
cost of equipment sales decreased to of revenue for the year ended december  compared to of revenue for the year ended december  in absolute dollars the costs remained level from year to year as the company realized substantial cost savings from the introduction of its transportable lithotripter even as total unit shipments doubled 
research and development costs increased by  or when compared to levels due to increased spending on the transportable lithotripter and continued development of the uts series of products 
selling expenses increased by  or  in when compared to due to the introductory advertising expenses for the medstone sts t transportable lithotripter and the company s trade show expenses for the medical imaging business 
general and administrative expenses increased by or  from to  due to the increased staffing costs for foreign operations  costs associated with the strategic planning process during and legal costs associated with actions against the company 
other income expense increased by  in when compared to due to recognition of gains on sale of cardiac science securities partially offset by an investment reserve in compared to the gain on sales of a joint venture in minority interest expense decreased to  in compared to  in due to a slight decrease in the per patient revenue and the corresponding effect on profitability 
provision for income taxes decreased due to a lower level of profitability in the current year when compared to the prior year 
liquidity and capital resources at december   the company had cash and short term investments of approximately million 
these funds were generated from operating activities 
during  the company purchased  shares of treasury stock for approximately  the company estimates that the purchase resulted in a increase in basic net income per share 
the company s long term capital expenditure requirements will depend upon numerous factors  including the progress of the company s research and development programs  the time required to obtain regulatory approvals  the resources that the company devotes to the development of self funded products  proprietary manufacturing methods and advanced technologies  the cost of acquisition and or new revenue opportunities  the ability of the company to obtain additional licensing arrangements and to manufacture products under those arrangements  the demand for its products if and when approved and possible acquisitions of products  technologies and companies 
the company believes that its existing working capital and funds anticipated to be generated from operations will be sufficient to meet the cash needs for continuation of its present operations during see safe harbor statement under the private securities litigation reform act of safe harbor statement under the private securities litigation reform act of forward looking statements in this report  including without limitation  statements relating to the company s plans  strategies  objectives  expectations  intentions and adequacy of resources  are made pursuant to the safe harbor provisions of the private securities litigation reform act of investors are cautioned that such forward looking statements involve risks and uncertainties including without limitation the following i the company s plans  strategies  objectives  expectations and intentions are subject to change at any time at the discretion of the company  ii the company s plans and results of operations will be affected by the company s ability to manage its growth  iii the company s businesses are highly competitive and the entrance of new competitors into or the expansion of the operations by existing competitors in the company s markets and other changes could adversely affect the company s plans and results of operations  and iv other risks and uncertainties indicated from time to time in the company s filings with the securities and exchange commission 
item a 
quantitative and qualitative disclosures about market risk the company has no financial instruments which are subject to market risk 
although the company s earnings and cash flows are subject to fluctuations due to changes in the interest rates on its investments  a hypothetical adverse decrease in the interest rates would not have a material adverse effect on the results of operations because the majority of the company s investments are short term treasury bills 
a reduction in interest rates would reduce interest income by approximately  annually 
due to the short period to maturity  the company believes that the impact of a reduction in interest rates would not have a material effect on the carrying value of its securities 
the company s earnings and cash flows at medstone international  ltd  a scottish subsidiary are subject to fluctuations due to changes in foreign currency rates 
the company believes that changes in the foreign currency exchange rate would not have a material adverse effect on its results of operations as the majority of its foreign transactions are delineated in medstone international  ltd 
s functional currency  the british pound 

